
According to the findings of an international, randomized, double-blind, placebo-controlled phase 3 clinical trial, adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy increases the survival of men with metastatic, hormone-sensitive prostate cancer.....